HYPERION DEFI, INC. Research and Development Expense
HYPERION DEFI, INC. (HYPD) reported Research and Development Expense of $58.49 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- HYPERION DEFI, INC. research and development expense for the quarter ending 2026-06-30 was $58.49K, a 91.33% decline year-over-year.
- HYPERION DEFI, INC. research and development expense for the quarter ending 2026-03-31 was $286.76K, a 57.39% decline year-over-year.
- HYPERION DEFI, INC. research and development expense for the quarter ending 2025-12-31 was $188.95K, a 90.37% decline year-over-year.
- HYPERION DEFI, INC. research and development expense for the quarter ending 2025-09-30 was $373.86K, a 89.23% decline year-over-year.
- HYPERION DEFI, INC. research and development expense for fiscal 2025 was $1.91M, a 86.79% decline from fiscal 2024.
- HYPERION DEFI, INC. research and development expense for fiscal 2024 was $14.46M, a 11.46% increase from fiscal 2023.
- HYPERION DEFI, INC. research and development expense for fiscal 2023 was $12.98M, a 3.01% decline from fiscal 2022.
- HYPERION DEFI, INC. research and development expense for fiscal 2022 was $13.38M, a 9.91% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $58.49K 10-Q · filed 2026-08-13 | $345.25K 10-Q · filed 2026-08-13 | $534.21K derived: sum of 3 quarters · filed 2026-08-13 | $908.06K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $286.76K 10-Q · filed 2026-05-15 | $475.72K derived: sum of 2 quarters · filed 2026-05-15 | $849.57K derived: sum of 3 quarters · filed 2026-05-15 | $1.52M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $188.95K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $562.81K derived: sum of 2 quarters · filed 2026-03-30 | $1.24M derived: sum of 3 quarters · filed 2026-08-13 | $1.91M 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $373.86K 10-Q · filed 2025-11-14 | $1.05M derived: sum of 2 quarters · filed 2026-08-13 | $1.72M 10-Q · filed 2025-11-14 | $3.68M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $674.58K 10-Q · filed 2026-08-13 | $1.35M 10-Q · filed 2026-08-13 | $3.31M derived: sum of 3 quarters · filed 2026-08-13 | $6.78M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $673.04K 10-Q · filed 2026-05-15 | $2.64M derived: sum of 2 quarters · filed 2026-05-15 | $6.11M derived: sum of 3 quarters · filed 2026-05-15 | $10.70M derived: sum of 4 quarters · filed 2026-05-15 | ||||
| 2024-12-31 | $1.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $5.43M derived: sum of 2 quarters · filed 2026-03-30 | $10.03M derived: sum of 3 quarters · filed 2026-03-30 | $14.46M 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | $3.47M 10-Q · filed 2025-11-14 | $8.07M derived: sum of 2 quarters · filed 2025-11-14 | $12.50M 10-Q · filed 2025-11-14 | $16.57M derived: sum of 4 quarters · filed 2025-11-14 | ||||
| 2024-06-30 | $4.60M 10-Q · filed 2025-08-13 | $9.03M 10-Q · filed 2025-08-13 | $13.09M derived: sum of 3 quarters · filed 2025-08-13 | $16.67M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | $4.43M 10-Q · filed 2025-05-19 | $8.50M derived: sum of 2 quarters · filed 2025-05-19 | $12.07M derived: sum of 3 quarters · filed 2025-05-19 | $14.89M derived: sum of 4 quarters · filed 2025-05-19 | ||||
| 2023-12-31 | $4.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $7.64M derived: sum of 2 quarters · filed 2025-04-15 | $10.45M derived: sum of 3 quarters · filed 2025-04-15 | $12.98M 10-K · filed 2025-04-15 | ||||
| 2023-09-30 | $3.58M 10-Q · filed 2024-11-12 | $6.39M derived: sum of 2 quarters · filed 2024-11-12 | $8.91M 10-Q · filed 2024-11-12 | $11.11M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | $2.81M 10-Q · filed 2024-08-14 | $5.33M 10-Q · filed 2024-08-14 | $7.54M derived: sum of 3 quarters · filed 2024-08-14 | $11.41M derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | $2.52M 10-Q · filed 2024-05-15 | $4.72M derived: sum of 2 quarters · filed 2024-05-15 | $8.60M derived: sum of 3 quarters · filed 2024-05-15 | $12.19M derived: sum of 4 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $6.08M derived: sum of 2 quarters · filed 2024-03-18 | $9.67M derived: sum of 3 quarters · filed 2024-03-18 | $13.38M 10-K · filed 2024-03-18 | ||||
| 2022-09-30 | $3.88M 10-Q · filed 2023-11-13 | $7.46M derived: sum of 2 quarters · filed 2023-11-13 | $11.18M 10-Q · filed 2023-11-13 | $14.47M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | $3.59M 10-Q · filed 2023-08-11 | $7.30M 10-Q · filed 2023-08-11 | $10.59M derived: sum of 3 quarters · filed 2023-08-11 | $14.14M derived: sum of 4 quarters · filed 2023-08-11 | ||||
| 2022-03-31 | $3.71M 10-Q · filed 2023-05-12 | $7.00M derived: sum of 2 quarters · filed 2023-05-12 | $10.56M derived: sum of 3 quarters · filed 2023-05-12 | $14.24M derived: sum of 4 quarters · filed 2023-05-12 | ||||
| 2021-12-31 | $3.29M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $6.84M derived: sum of 2 quarters · filed 2023-03-31 | $10.53M derived: sum of 3 quarters · filed 2023-03-31 | $14.85M 10-K · filed 2023-03-31 | $14.51M 10-K · filed 2022-03-30 | |||
| 2021-09-30 | $3.55M 10-Q · filed 2022-11-14 | $3.47M 10-Q · filed 2021-11-12 | $7.24M derived: sum of 2 quarters · filed 2022-11-14 | $11.56M 10-Q · filed 2022-11-14 | $11.33M 10-Q · filed 2021-11-12 | $15.01M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $3.68M 10-Q · filed 2022-08-11 | $3.62M 10-Q · filed 2021-08-12 | $8.01M 10-Q · filed 2022-08-11 | $7.86M 10-Q · filed 2021-08-12 | $11.46M derived: sum of 3 quarters · filed 2022-08-11 | $14.82M derived: sum of 4 quarters · filed 2022-08-11 | ||
| 2021-03-31 | $4.32M 10-Q · filed 2022-05-13 | $4.25M 10-Q · filed 2021-05-14 | $7.77M derived: sum of 2 quarters · filed 2022-05-13 | $11.14M derived: sum of 3 quarters · filed 2022-05-13 | $14.05M derived: sum of 4 quarters · filed 2022-05-13 | |||
| 2020-12-31 | $3.45M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $6.81M derived: sum of 2 quarters · filed 2022-03-30 | $9.73M derived: sum of 3 quarters · filed 2022-03-30 | $13.36M 10-K · filed 2022-03-30 | $13.26M 10-K · filed 2021-03-30 | |||
| 2020-09-30 | $3.36M 10-Q · filed 2021-11-12 | $6.28M derived: sum of 2 quarters · filed 2021-11-12 | $9.91M 10-Q · filed 2021-11-12 | $13.24M derived: sum of 4 quarters · filed 2021-11-12 | ||||
| 2020-06-30 | $2.92M 10-Q · filed 2021-08-12 | $6.55M 10-Q · filed 2021-08-12 | $9.87M derived: sum of 3 quarters · filed 2021-08-12 | $13.08M derived: sum of 4 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | $3.63M 10-Q · filed 2021-05-14 | $6.96M derived: sum of 2 quarters · filed 2021-05-14 | $10.16M derived: sum of 3 quarters · filed 2021-05-14 | $13.73M derived: sum of 4 quarters · filed 2021-05-14 | ||||
| 2019-12-31 | $3.32M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $6.53M derived: sum of 2 quarters · filed 2021-03-30 | $10.09M derived: sum of 3 quarters · filed 2021-03-30 | $14.10M 10-K · filed 2021-03-30 | ||||
| 2019-09-30 | $3.20M 10-Q · filed 2020-11-12 | $6.77M derived: sum of 2 quarters · filed 2020-11-12 | $10.78M 10-Q · filed 2020-11-12 | $14.90M derived: sum of 4 quarters · filed 2020-11-12 | ||||
| 2019-06-30 | $3.57M 10-Q · filed 2020-08-14 | $7.58M 10-Q · filed 2020-08-14 | $11.70M derived: sum of 3 quarters · filed 2020-08-14 | $14.19M derived: sum of 4 quarters · filed 2020-08-14 | ||||
| 2019-03-31 | $4.01M 10-Q · filed 2020-05-14 | $8.13M derived: sum of 2 quarters · filed 2020-05-14 | $10.62M derived: sum of 3 quarters · filed 2020-05-14 | $13.03M derived: sum of 4 quarters · filed 2020-05-14 | ||||
| 2018-12-31 | $4.13M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | $6.61M derived: sum of 2 quarters · filed 2020-03-30 | $9.03M derived: sum of 3 quarters · filed 2020-03-30 | $11.12M 10-K · filed 2020-03-30 | ||||
| 2018-09-30 | $2.49M 10-Q · filed 2019-11-13 | $4.90M derived: sum of 2 quarters · filed 2019-11-13 | $6.99M 10-Q · filed 2019-11-13 | $8.58M derived: sum of 4 quarters · filed 2019-11-13 | ||||
| 2018-06-30 | $2.41M 10-Q · filed 2019-08-13 | $4.51M 10-Q · filed 2019-08-13 | $6.09M derived: sum of 3 quarters · filed 2019-08-13 | $6.66M derived: sum of 4 quarters · filed 2019-08-13 | ||||
| 2018-03-31 | $2.09M 10-Q · filed 2019-05-14 | $3.68M derived: sum of 2 quarters · filed 2019-05-14 | $4.25M derived: sum of 3 quarters · filed 2019-05-14 | $5.00M derived: sum of 4 quarters · filed 2019-05-14 | ||||
| 2017-12-31 | $1.58M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-27 | $2.15M derived: sum of 2 quarters · filed 2019-03-27 | $2.91M derived: sum of 3 quarters · filed 2019-03-27 | $3.82M 10-K · filed 2019-03-27 | ||||
| 2017-09-30 | $570.42K 10-Q · filed 2018-11-13 | $1.32M derived: sum of 2 quarters · filed 2018-11-13 | $2.23M 10-Q · filed 2018-11-13 | |||||
| 2017-06-30 | $751.93K 10-Q · filed 2018-08-14 | $1.66M 10-Q · filed 2018-08-14 | ||||||
| 2017-03-31 | $910.84K 10-Q · filed 2018-05-09 | |||||||
| 2016-12-31 | $2.97M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |